Benlysta Continues to Gain Increased Market Share among U.S. Rheumatologists Six-Months Post-Launch

More rheumatologists are prescribing Benlysta for lupus

The LaunchTrends(R): Benlysta Wave 3 report, which measures product uptake and commercial effectiveness at six months post launch, finds that over half of surveyed rheumatologists have initiated trial on Benlysta, up from 36% at three months post-launch and significantly higher than 25% at one month post-launch. One of the most notable shifts in prescribing since one month post-launch is a significant increase in current Benlysta shares for the moderate and severe patient groups.


Comments are closed.